


Thalidomide-azetidone-piperazine-C2-O-C2-OH

Cat. No.:	HY-161191
Molecular Formula:	C ₂₄ H ₃₁ N ₅ O ₆
Molecular Weight:	485.53
Target:	Ligands for E3 Ligase; Autophagy
Pathway:	PROTAC; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Thalidomide-azetidone-piperazine-C2-O-C2-OH is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. Thalidomide-azetidone-piperazine-C2-O-C2-OH can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
IC ₅₀ & Target	Cereblon (CRBN) ^[1]

REFERENCES

- [1]. Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. *Nature*. 2014 Aug 7;512(7512):49-53.
- [2]. Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. *Med Sci Monit*. 2018 May 15;24:3193-3203.
- [3]. Bian C, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. *Free Radic Biol Med*. 2018 Dec;129:446-453.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA